TrialHaematologica2015

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.

Andrew H Lipsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.